LetterStem Cells

Response to Comment on “Drug Screening for ALS Using Patient-Specific Induced Pluripotent Stem Cells”

Science Translational Medicine  05 Jun 2013:
Vol. 5, Issue 188, pp. 188lr2
DOI: 10.1126/scitranslmed.3005697

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Our work and the study of Bilican et al. highlight the need for complementary assays to detect subtle phenotypic differences between control and mutant induced pluripotent stem cell lines.

View Full Text